Status:
COMPLETED
Effects of 2 Different Duration of Albendazole Therapy in Patients With Neurocysticercosis in Brain ≤ 5 Lesions on CT
Lead Sponsor:
All India Institute of Medical Sciences
Conditions:
Neurocysticercosis
Eligibility:
All Genders
2-18 years
Phase:
PHASE3
Brief Summary
Comparing the effect of two different duration of same drug albendazole in patients with Neurocysticercosis less than or equal to 5 lesions on CT head at the end of 6 months.
Detailed Description
The trial will be comparing the effectiveness of short and long duration of albendazole ie 7 and 28 days therapy in patients with parenchymal neurocysticercosis in terms of complete resolution or calc...
Eligibility Criteria
Inclusion
- Age 2-18 years.
- Number of parenchymal lesions: upto 5\*
- Stages of cysticerci at which albendazole treatment is effective
- Vesicular stage
- Colloid vesicular stage
- Granular nodular stage
Exclusion
- Cysticercotic encephalitis
- Calcified cyst
- Hydrocephalus
- Intraventricular cyst
- Subarachnoid cyst
- Ophthalmic Cysticercosis
- No of cysts \>5
- Known allergy to benzimidazole class of compound which includes anaphylaxis, hypotension, severe skin reactions .
- Features of raised ICT (papilloedema, hyperventilation, hypertension, tonic posturing, B/L 6th nerve palsy, features of midline shift on CT/MRI)
- Critically sick (respiratory failure, cardiovascular instability)
- Already received albendazole or praziquantel or steroid therapy
Key Trial Info
Start Date :
March 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2015
Estimated Enrollment :
97 Patients enrolled
Trial Details
Trial ID
NCT02243644
Start Date
March 1 2014
End Date
October 1 2015
Last Update
January 1 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
sheffali Gulati
New Delhi, National Capital Territory of Delhi, India, 110029